Medxy AI

Seasonal Malaria Chemoprevention in Uganda: Efficacy of SPAQ and Dihydroartemisinin-Piperaquine in the Era of Drug Resistance

By MedXY 08/03/2025

A large cluster-randomised trial in Uganda demonstrates that both SPAQ and dihydroartemisinin-piperaquine are highly effective and safe for seasonal malaria chemoprevention in children, with no evidence of resistance selection.

Clinical Updates Wellness & Lifestyle

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

By MedXY 08/03/2025

The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.

Clinical Updates Wellness & Lifestyle

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

By MedXY 08/03/2025

Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.

Clinical Updates Wellness & Lifestyle

Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial

By MedXY 08/03/2025

The DISTRICTS trial demonstrates that initial surgical treatment for carpal tunnel syndrome leads to significantly higher recovery rates at 18 months compared to starting with corticosteroid injections, despite similar adverse event profiles.

Clinical Updates Wellness & Lifestyle

Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?

By MedXY 08/03/2025

Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.

Clinical Updates Wellness & Lifestyle

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

By MedXY 08/03/2025

The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic toxicity.

Clinical Updates Wellness & Lifestyle

Online Video Versus Face-to-Face Preoperative Consultation for Major Abdominal Surgery: Insights from the VIDEOGO Non-Inferiority Trial

By MedXY 08/03/2025

The VIDEOGO trial shows that online video consultations are non-inferior to face-to-face consultations for preoperative assessment in major abdominal surgery, achieving similar patient satisfaction and information recall.

Clinical Updates Wellness & Lifestyle

Targeted Pneumococcal Vaccination in New Older Adult Care Home Residents: Evidence from National Surveillance in England

By MedXY 08/03/2025

Vaccinating new older adult care home residents with PCV20 or PPV23 could prevent substantially more invasive pneumococcal disease cases and deaths per dose than standard age-based vaccination, supporting policy revision.

Clinical Updates

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

By MedXY 08/03/2025

MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.

Clinical Updates Wellness & Lifestyle

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

By MedXY 08/03/2025

A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.

Seasonal Malaria Chemoprevention in Uganda: Efficacy of SPAQ and Dihydroartemisinin-Piperaquine in the Era of Drug Resistance

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial

Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

Online Video Versus Face-to-Face Preoperative Consultation for Major Abdominal Surgery: Insights from the VIDEOGO Non-Inferiority Trial

Targeted Pneumococcal Vaccination in New Older Adult Care Home Residents: Evidence from National Surveillance in England

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

Silent Damage: Blood Pressure and Subclinical Cardiovascular Injury in Adolescents—Insights from the SHIP AHOY Study

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained

Beyond Negative: Quantitative Fecal Hemoglobin Levels Refine Colorectal Cancer Risk Stratification in FIT-based Screening

Overcoming PD-1 Inhibitor Resistance: Six Emerging Strategies from the 2025 ASCO Annual Meeting